Fri Sep 09 2022

115 articles - From Friday Sep 02 2022 to Friday Sep 09 2022

parm_toc.knit

Guidelines

Guidelines, position statements, white papers, technical reviews, consensus statements, etc…

Lancet Haematol

Development of an international standard set of outcome measures for patients with venous thromboembolism: an International Consortium for Health Outcomes Measurement consensus recommendation.

Additional measures can be introduced to the user by a cascade opt-in system that allows for further assessment if required. This set of outcomes and measurement tools will facilitate the implementation of the use of patient-centred outcomes in daily practice.

Pubmed   Journal   ReadQx 


Meta-analysis

meta-analyses and systematic reviews

Blood Adv

Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: A systematic review and meta-analysis.

Frontline addition of caplacizumab does not significantly reduce all-cause mortality compared with SOC alone, although it reduces refractory disease risk, shortens time-to-response, and improves exacerbation rates, at the expense of increased relapse and bleeding risk.

Pubmed   Journal   ReadQx 


Original articles

RCT, clinical trials, retrospective studies, etc…

Am J Hematol

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry.

Colorectal, prostate, and lung cancer risks were lower than expected. These findings help advance care of patients with GD1 by supporting recommendations for individualized monitoring for malignancies and antecedents such as MGUS for MM and provoke important questions of the role of glucosylceramide and related sphingolipids in cancer biology.

Pubmed   Journal   ReadQx 

Contemporary outcomes in IDH-mutated AML: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.

Differing outcomes were observed in IDH1 mut vs IDH2 mut or NPM1 mut AML which were influenced by co-occurring NPM1 mutations and partially abrogated with venetoclax-based therapy. Given the differing biology and survival in IDH1 mut AML, investigations incorporating molecularly targeted therapies such as IDH inhibitors remain warranted in this subgroup.

Pubmed   Journal   ReadQx 

Converting Adults with Sickle Cell Disease from Full Agonist Opioids to Buprenorphine: A Reliable Method with Safety and Early Evidence of Reduced Acute Care Utilization.

At six months follow-up, five participants had discontinued buprenorphine (16.67%), and overall acute care visits dropped from a mean of 10.50 (SD 11.35) in the six months pre-induction to 2.89 (SD 3.40) in the six months post induction. In an appropriately interdisciplinary care setting, buprenorphine shows promise as a safe alternative to chronic opioid therapy with early evidence of benefit for high utilizing patients with SCD.

Pubmed   Journal   ReadQx 

Efficacy of pp65-specific TCR-T cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation.

Among them, 2 patients have survived for more than one year. This study demonstrates the great potential in the treatment and prevention of CMV infection following HSCT or other organ transplantation.

Pubmed   Journal   ReadQx 

Erythroferrone contributes to iron mobilization for embryo erythropoiesis in iron-deficient mouse pregnancies.

The effect was exacerbated under iron-deficient conditions where ERFE KO embryos had higher hepcidin, lower Hb and Hct, and lower brain iron concentration compared to WT embryos, indicative of iron restriction. Thus, under iron-deficient conditions, maternal and embryo ERFE facilitate iron mobilization for embryonic erythropoiesis.

Pubmed   Journal   ReadQx 

Functional role of endothelial transferrin receptor 1 in iron sensing and homeostasis.

Finally, ferritin and non-transferrin bound iron (NTBI) are additional sources of iron that mediate Bmp6 induction in primary liver endothelial cell cultures via TFR1-independent mechanisms. Together, our data demonstrate a minor functional role for endothelial cell TFR1 in iron uptake, BMP6 regulation, and hepatocyte hepcidin regulation under iron limiting conditions, and suggest that ferritin and/or NTBI uptake by other transporters have a dominant role when iron availability is high.

Pubmed   Journal   ReadQx 

Long-term outcomes and predictors of early response, late relapse and survival for patients treated with bispecific LV20.19 CAR T-cells.

Bridging therapy and higher absolute lymphocyte count on day of CAR-T infusion were associated with inferior survival outcomes. In conclusion, this initial trial of LV20.19 CAR-T demonstrates a signal for favorable long-term outcomes for patients with R/R B-cell malignancies.

Pubmed   Journal   ReadQx 

Low-dose dasatinib 50mg/day versus standard-dose dasatinib 100mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.

The rate of any grade pleural effusion was 5% with dasatinib 50mg/day compared to 21% with 100mg/day. Dasatinib 50mg/day is at least as effective as 100mg/day with a better safety profile and drug exposure.

Pubmed   Journal   ReadQx 

Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.

Ponatinib shows high response rates and robust survival outcomes in patients whose disease failed prior to 2G TKIs, including patients with T315I mutation. The response-based dosing in OPTIC led to improved safety and similar efficacy outcomes compared with PACE.

Pubmed   Journal   ReadQx 

Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients.

FLAG-GO regimen was superior in optimal disease specific fusion transcript reduction at end of induction (p=0.002,), mid-consolidation (p<0.01) and end of consolidation (p<0.001) therapy. Induction/consolidation with FLAG-GO regimen results in better clinical outcomes in newly diagnosed patients with CBF-AML compared to FLAG-IDA and achieves deeper molecular clearance by qPCR assessment of the fusion transcripts.

Pubmed   Journal   ReadQx 

Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma.

Revised MALT-IPI is a new index centered on disease characteristics that provides robust risk-stratification identifying a group of patients characterized by earlier progression of disease. Revised MALT-IPI can allow a more disease-adjusted management of patients with EMZL in clinical trials and practice.

Pubmed   Journal   ReadQx 

Safety and Efficacy of Jaktinib in the Treatment of Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis: Results of a Phase II Trial.

All non-hematological TEAEs were mild. These results indicate that jaktinib can shrink the spleen, improve anemia, and other clinical symptoms with good tolerability.

Pubmed   Journal   ReadQx 

The significance of spleen size in children with sickle cell anemia.

Finally, we found a strong association between erythrocyte deformability measured with oxygen gradient ektacytometry, spleen size, and PIT counts. In conclusion, our results do not agree with the general perception that most children with SCA undergo autosplenectomy within the first decade of life and indicate that loss of erythrocyte deformability contributes to loss of splenic filtration capacity in SCA, as well as phenotypical variations in spleen size.

Pubmed   Journal   ReadQx 

Time-dependent prediction of mortality and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation using machine learning.

These gradient boosting machine models provide well-calibrated, time-dependent risk predictions and achieved areas under the receiver-operating characteristic of 0.92 and 0.83 and areas under the precision-recall curve of 0.58 and 0.62 for prediction of mortality and CMV reactivation, respectively, in a 21-day time window. Both models were successfully validated in a prospective, non-interventional study and performed on par with expert hematologists in a pilot comparison.

Pubmed   Journal   ReadQx 

Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent ß-thalassemia.

Remarkably, BM Tfr2 deletion is also sufficient to avoid long-term blood transfusions required for survival of Hbb th1/th2 animals, preventing mortality due to chronic anemia and reducing transfusion-associated complications, such as progressive iron-loading. Altogether, TFR2 targeting might represent a promising therapeutic option also for TDT.

Pubmed   Journal   ReadQx 

Understanding pulse oximetry in hematology patients: Hemoglobinopathies, racial differences and beyond.

In addition, a range of challenges may arise in patients with increased levels of methemoglobin - whether acquired or inherited - carboxyhemoglobin, or in patients with a subset of inherited variant hemoglobins. It is important for Hematologists, and indeed al clinicians who rely on pulse oximetry, to understand the principles and limitations of this ubiquitous test.

Pubmed   Journal   ReadQx 

Ann Oncol

An international open-label randomised trial comparing a two-step approach versus the standard three-step approach of the WHO analgesic ladder in patients with cancer.

This trial provides some evidence that the two-step approach is an alternative option for cancer pain management.

Pubmed   Journal   ReadQx 

Leveraging Big Data of Immune Checkpoint Blockade Response Identifies Novel Potential Targets.

Our study highlights the potential of large-scale meta-analyses in identifying novel biomarkers and potential therapeutic targets for cancer immunotherapy.

Pubmed   Journal   ReadQx 

Blood

A randomized trial of blood donor iron repletion on red cell quality for transfusion and donor cognition and wellbeing.

Iron repletion did not affect any cognition or wellbeing measures. These data provide evidence that current criteria for blood donation preserve red cell transfusion quality for the recipient and protect adult donors from measurable effects of blood donation-induced iron deficiency on cognition.

Pubmed   Journal   ReadQx 

Antigen-guided depletion of anti-HLA antibody-producing cells by HLA-Fc fusion proteins.

These results support HLA-Fc as a novel strategy for antigen-specific humoral suppression to improve transfusion and transplantation outcomes. With the long-term goal of targeting HLA-specific memory B cells for desensitization, further studies of HLA-Fc's efficacy in immune-competent animal models are warranted.

Pubmed   Journal   ReadQx 

Epo-IGF1R crosstalk expands stress-specific progenitors in regenerative erythropoiesis and myeloproliferative neoplasm.

In myeloproliferative neoplasm patient samples, the number of sCFU-E like cells increases, and inhibition of IGR1R/IRS2 signaling blocks Epo-hypersensitive erythroid cell colony formation. In summary, we identify a new stress-specific erythroid progenitor cell population that links regenerative erythropoiesis to pathogenic erythrocytosis.

Pubmed   Journal   ReadQx 

Immune thrombocytopenia and pregnancy: an exposed/non-exposed cohort study.

NITP is associated with NITP history and the severity of maternal ITP during pregnancy. These results will be useful for counseling ITP women.

Pubmed   Journal   ReadQx 

Perioperative diagnosis and impact of acquired von Willebrand syndrome in infants with congenital heart disease.

The GPIbM/VWF:Ag ratio is a reliable test that can be included in routine intraoperative laboratory workup. Our data provide the basis for further studies in larger patient cohorts to achieve definitive clarification of the effects of aVWS and its potential treatment on intraoperative bleeding.

Pubmed   Journal   ReadQx 

Blood Adv

A conformational transition of the D'D3 domain primes von Willebrand factor for multimerization.

Furthermore, we find a stabilization of the interface in the presence of coagulation factor VIII, providing evidence for a previously hypothesized binding site in submodule C8-3. Our findings highlight the critical role of the D'D3 domain in VWF biosynthesis and function, and we anticipate our methodology to be applicable to study other, similar conformational changes in VWF and beyond.

Pubmed   Journal   ReadQx 

Brentuximab vedotin plus adriamycin and dacarbazine in nonbulky limited-stage Hodgkin lymphoma: results of a phase 2 trial.

This trial is registered on clinicaltrials. gov (NCT02505269).

Pubmed   Journal   ReadQx 

Long-term proliferation of immature hypoxia-dependent JMML cells supported by a 3D in vitro system.

Our study contributes to the development of a robust JMML 3D in vitro model to study and define the impact of microenvironment stimuli on JMML disease and the molecular mechanisms regulating JMML initiating and propagating cells. Pd-JAO may become a promising model for compound tests focusing on new therapeutic intervention aiming to eradicate JMML progenitors and control JMML disease.

Pubmed   Journal   ReadQx 

Proinflammatory microenvironment promotes lymphoma progression in mice with high megakaryocyte and TPO levels.

Moreover, RNA sequencing of blood-resident Eµ-myclymphoma cells from TpoTgand wild-type mice after tumour transplant revealed upregulation of hallmark gene sets associated with inflammatory response in TpoTg mice. We propose that a pro-inflammatory microenvironment in TpoTgmice promoted lymphoma progression.

Pubmed   Journal   ReadQx 

Prospective hemophilia inhibitor PUP study reveals distinct antibody signatures during FVIII inhibitor eradication.

Interestingly, one patient with partial ITI success and one patient with ITI failure developed apparent oligoreactive FVIII-binding antibodies during ITI. The explanation of the true nature of these antibodies requires more comprehensive follow-ups in future studies.

Pubmed   Journal   ReadQx 

Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children.

In available pre-HCT samples, there were no differences in complement biomarkers in those with SCD and those without, though SCD patients did have significantly higher markers of endothelial activation, sVCAM-1 and p-selectin levels. In conclusion, children with SCD merit careful screening for TA-TMA post HCT, particularly those receiving a haploidentical HCT.

Pubmed   Journal   ReadQx 

TCRvß-CART therapy mediates high precision targeting of malignant T-cell clones.

Importantly, in al cases the non-targeted TCRvb families were spared. Thus, TCRvb-CART therapy provides a potential option for high-precision treatment of PTCL with limited healthy T-cell depletion.

Pubmed   Journal   ReadQx 

The outcome of older adults with classic Hodgkin lymphoma in British Columbia.

With a median follow-up of 9 years, 5-year disease specific (DSS) and overall survival (OS) have improved by decade comparison (both p 70 even in the mod-ern treatment era. Further, treatment-related toxicity remains a significant concern and use of bleo-mycin should be avoided in most patients.

Pubmed   Journal   ReadQx 

Uncoupling of platelet granule release and integrin activation suggests GPIIb/IIIa as therapeutic target in COVID-19.

These thrombi were susceptible to subthreshold levels of GPIIb/IIIa blockers eptifibatide or tirofiban that had only a minor effect in control blood. We provide evidence that low dose GPIIb/IIIa blockade could be a therapeutic approach in COVID-19.

Pubmed   Journal   ReadQx 

Blood Cancer J

Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib.

Among patients with CLL disease progression on ibrutinib, OS was significantly longer when next-line treatment was chimeric antigen receptor T-cell therapy (median not reached) or venetoclax-based treatment (median 29.8months) compared to other approved treatments, such as chemoimmunotherapy, phosphoinositide 3'-kinase inhibitors, and anti-CD20 monoclonal antibodies (9.1months; p=0.03). These findings suggest an unmet need for this growing patient population.

Pubmed   Journal   ReadQx   PMC

Two-drug versus three-drug induction chemotherapy in pediatric acute myeloid leukemia: a randomized controlled trial.

There was no statistically significant difference in EFS, OS, CR, or toxicity between ADE and DA regimens in pediatric AML. The trial was registered with the Clinical Trial Registry of India (Reference number: CTRI/2014/11/005202).

Pubmed   Journal   ReadQx 

Haematologica

Activation of lncRNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins.

Overall, we provided novel important insights into NEAT1 role in supporting MM cells adaptation to stressful conditions by improving the maintenance of DNA integrity. Taken together, our results suggest that NEAT1, and probably PS organelles, could represent a potential therapeutic target for MM treatment.

Pubmed   Journal   ReadQx 

Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival.

Not available.

Pubmed   Journal   ReadQx 

Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial.

Not available.

Pubmed   Journal   ReadQx 

Targeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in Tcell acute lymphoblastic leukemia.

TAL1-positive, AKT-activated T-ALL cells were very sensitive to PIK-75, as evidenced by the growth inhibition and apoptosis induction, while T-ALL cells that exhibited activation of the JAK-STAT pathway were insensitive to this drug. Together, our study demonstrates a strategy targeting two types of core machineries mediated by oncogenic transcription factors and signaling pathways in T-ALL.

Pubmed   Journal   ReadQx 

Treatment patterns and clinical outcomes of asciminib in a real-world multi-resistant chronic myeloid leukemia patient population.

Not available.

Pubmed   Journal   ReadQx 

J Hematol Oncol

Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1.

We found that circPDK1 was activated by HIF1A at the transcriptional level by modulating the miR-628-3p/BPTF axis and degrading BIN1. Exosomal circPDK1 is a promising biomarker for PC diagnosis and prognosis and represents a potential therapeutic target for PC.

Pubmed   Journal   ReadQx 

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation.

In this large as-treated analysis, we showed that alloHCT is able to overcome the negative prognostic impact of certain IDH mutational subclasses in first-line consolidation treatment and could pending prognostic validation, provide prognostic value for AML risk stratification and therapeutic decision making.

Pubmed   Journal   ReadQx   PMC

Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.

In summary, we developed and validated a sensitive and cost-effective method for untargeted ctDNA detection at diagnosis as well as for treatment monitoring of al CRC patients based on genetic as well as non-genetic tumor-specific cfDNA features. Thus, once sensitivity and specificity have been externally validated, LIFE-CNA has the potential to be implemented into clinical practice. To the best of our knowledge, this is the first study to consider multiple genetic and non-genetic cfDNA features in combination with ML classifiers and to evaluate their potential in both cancer detection and treatment monitoring.

Pubmed   Journal   ReadQx   PMC

Lancet Haematol

Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.

Interpretation Azacitidine with venetoclax is safe and shows encouraging activity in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia. Funding MD Anderson Cancer Center.

Pubmed   Journal   ReadQx 

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.

Interpretation The durability of improved haematological outcomes and favourable safety profile over 48 weeks of treatment suggests that pegcetacoplan has the potential to improve treatment benefit and alter treatment goals in patients with paroxysmal nocturnal haemoglobinuria. Funding Apellis Pharmaceuticals.

Pubmed   Journal   ReadQx 

Leukemia

Pregnancy and childbirth outcomes in women with myeloproliferative neoplasms-a nationwide population-based study of 342 pregnancies in Sweden.

Incidence was 12.2 per 100.000 pregnancies. In summary, preterm birth was an important complication in MPN pregnancies, while maternal complications were less common than previously reported.

Pubmed   Journal   ReadQx 

Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.

Sequential analysis of variant allelic frequency of mutations like SRSF2 did not reveal an impact of ROM on clonal evolution in both responders and non-responders. In summary, our study confirms the safety and efficacy of ROM in LR-MDS patients and may allow to better define subgroups of patients with a high likelihood of response.

Pubmed   Journal   ReadQx 

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML.

Our data suggest that the leupaxin-PTK2B axis plays an important role in acquired TKI resistance in AML. PTK2B/FAK inhibitors act synergistically with currently used therapeutics and may overcome emerging TKI resistance in FLT3-mutated AML at an early timepoint.

Pubmed   Journal   ReadQx 

Thromb Haemost

Hemostatic Effects of Tranexamic Acid in Cesarean Delivery: An Ancillary Study of the TRAAP2 Study.

GFC/LT evidenced fibrinolysis activation during cesarean delivery, linked to a decrease in fibrinolytic inhibitors. GFC/LT revealed a significant antifibrinolytic effect of TXA compared with placebo.

Pubmed   Journal   ReadQx 

Of mice and man - The unwinding of CLEC-2 as an anti-thrombotic target?

N/A.

Pubmed   Journal   ReadQx 

Parenteral Antiplatelet Drugs in ST-Elevation Myocardial Infarction: Current Status and Future Directions.

Novel parenteral antiplatelet drugs, such as cangrelor, selatogrel, and zalunfiban, have been recently developed to achieve rapid, potent antiplatelet effects while preserving hemostasis. We provide a description of currently available parenteral antiplatelet agents and of those in clinical development for prehospital administration in STEMI patients.

Pubmed   Journal   ReadQx 

Protein Tyrosine Phosphatase 1B Deficiency in Vascular Smooth Muscle Cells Promotes Perivascular Fibrosis following Arterial Injury.

SMAD2 siRNA transfection increased protein levels of PDGFRß and MYH10 while reducing ERK1/2 phosphorylation, thus phenocopying genetic PTP1B deletion. Chronic reduction of PTP1B in SMCs promotes dedifferentiation, perivascular fibrosis, and adverse remodeling following vascular injury by mechanisms involving an ERK1/2 phosphorylation-driven shift from SMAD2 to KLF4-regulated gene transcription.

Pubmed   Journal   ReadQx 


Reviews&Editorials

Plenty of the editorials are available as full text through the publisher website using the provided link

Am J Hematol

HbSC disease: A time for progress.

Pubmed   Journal   ReadQx 

Jaktinib (JAK1/2 inhibitor): a momelotinib derivative with similar activity and optimized dosing schedule.

Pubmed   Journal   ReadQx 

The Forgotten Survivor: A comprehensive review on Non-Hodgkin Lymphoma Survivorship.

The latter includes CAR T-cell therapy, monoclonal antibodies, checkpoint inhibitors, and hematopoietic stem cell transplantation. In this report, we aim to shed the light on these aspects in addition to discuss survivorship care plan for NHL.

Pubmed   Journal   ReadQx 

Blood

A virtuosic CADENZA played by sutimlimab.

Pubmed   Journal   ReadQx 

Bispecifics need a mindful pause.

Pubmed   Journal   ReadQx 

CHIP and gout: trained immunity?

Pubmed   Journal   ReadQx 

Desmopressin revisited in mild hemophilia A.

Pubmed   Journal   ReadQx 

Grab and go: transferrin uptake in erythropoiesis.

Pubmed   Journal   ReadQx 

HSCs: slow me down with PLAG1.

Pubmed   Journal   ReadQx 

In APL, noncoding mutations and SNP converge on WT1.

Pubmed   Journal   ReadQx 

MCD-DLBCL arises from germinal center B cells.

Pubmed   Journal   ReadQx 

MDM2 inhibition augments GVL effect.

Pubmed   Journal   ReadQx 

More than reverting tyrosine kinases.

Pubmed   Journal   ReadQx 

NETs in sickle cell disease, quo vadis?

Pubmed   Journal   ReadQx 

Radiotherapy is here to stay.

Pubmed   Journal   ReadQx 

To transplant or not to transplant: that is the question in PTCL.

Pubmed   Journal   ReadQx 

Blood Cancer J

Smoldering multiple myeloma current treatment algorithms.

Patients with newly diagnosed high risk SMM should be offered therapy with lenalidomide or lenalidomide plus dexamethasone (Rd) for 2 years, or enrollment in clinical trials. Patients with low risk SMM should be observed without therapy every 3-4 months.

Pubmed   Journal   ReadQx 

J Hematol Oncol

ASXL1/2 mutations and myeloid malignancies.

ASXL1 mutations frequently occur in myeloid malignancies and are associated with a poor prognosis, whereas ASXL2 mutations frequently occur in AML with t(8; 21)/RUNX1-RUNX1T1 and less frequently in other subtypes of myeloid malignancies. Herein, we review the role of ASXL1 and ASXL2 in normal and malignant hematopoiesis by summarizing the findings of mouse model systems and discussing their underlying molecular mechanisms.

Pubmed   Journal   ReadQx 

Lancet Haematol

Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years.

In response to the programme, some governments increased investment in haemophilia care, including independent purchases of small amounts of treatment products. With unparalleled scope and complexity, and substantial benefits to people with haemophilia and society in general, the WFH HAP is an exemplar of partnership between for-profit and not-for-profit organisations advancing health-care equity in LICs and LMICs, which could be replicated by other organisations supporting people with different monogenic diseases.

Pubmed   Journal   ReadQx 

UK Infected Blood Inquiry: long-awaited progress?

Pubmed   Journal   ReadQx 


Miscellaneous

misc publications eg case reports, tools of the trade, images of the month, etc…

Am J Hematol

Multiple Myeloma with Central Nervous System Relapse Presenting as Right Pupil-Sparing Complete Third Nerve Palsy.

Pubmed   Journal   ReadQx 

Blood

Heward J, Konali L, D'Avola A, et al. KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. Blood. 2021;138(5):370-381.

Pubmed   Journal   ReadQx 

Paroxysmal Nocturnal Hemoglobinuria: Experience of compassionate use pegcetacoplan.

Pubmed   Journal   ReadQx 

Progression of CCND1- in situ mantle cell neoplasia to CCND1- mantle cell lymphoma.

Pubmed   Journal   ReadQx 

Visceral leishmaniasis in the differential diagnosis of pancytopenia.

Pubmed   Journal   ReadQx 

Blood Adv

Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation.

Pubmed   Journal   ReadQx 

Chemokines IP-10/CXCL10 and IL-8/CXCL8 are potential novel biomarkers of warm autoimmune hemolytic anemia.

Pubmed   Journal   ReadQx 

CA Cancer J Clin

Medicaid expansion increases survival for patients with cancer.

Pubmed   Journal   ReadQx 

Smoking cessation support lags behind lung cancer screenings.

Pubmed   Journal   ReadQx 

Haematologica

Images from the Haematologica Atlas of Hematologic Cytology: schistocytes in thrombotic microangiopathies.

Pubmed   Journal   ReadQx 

The beginnings of molecular medicine.

Pubmed   Journal   ReadQx 

Lancet Haematol

A roadmap during parenting.

Pubmed   Journal   ReadQx 

An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes.

Pubmed   Journal   ReadQx 

Control participants of randomised trials: an often forgotten, vulnerable population.

Pubmed   Journal   ReadQx 

Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war.

Pubmed   Journal   ReadQx 

Pegcetacoplan: climbing up the complement cascade.

Pubmed   Journal   ReadQx 


Letters&Replies

Letters to the editors and authors’ replies

Am J Hematol

A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer.

Pubmed   Journal   ReadQx 

Adherence to NHLBI guidelines for the emergent management of vaso-occlusive episodes in children with sickle cell disease: A multicenter perspective.

Pubmed   Journal   ReadQx 

Adoptive transfer of functional SARS-COV-2-specific immunity from donor graft to hematopoietic stem cell transplant recipients.

Pubmed   Journal   ReadQx 

Caplacizumab for congenital thrombotic thrombocytopenic purpura.

Caplacizumab rapidly increased platelet count which likely shorted the hospital stay and reduced plasma transfusion requirement.

Pubmed   Journal   ReadQx 

CD19-Directed Immunotherapy Use in KMT2A-Rearranged Acute Leukemia: A Case Report and Literature Review of Increased Lymphoid to Myeloid Lineage Switch.

Pubmed   Journal   ReadQx 

Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission.

Recurrence of MRD in AML is associated with imminent relapse unless intervened upon. Change in chemotherapy regimen and/or immediate transplant improve outcomes.

Pubmed   Journal   ReadQx 

Co-expression of mutated Jak2 and Calr enhances myeloproliferative phenotype in mice without loss of stem cell fitness.

Pubmed   Journal   ReadQx 

Erythrocytic vacuoles that accumulate a fluorescent dye predict spleen size and function in sickle cell disease.

Pubmed   Journal   ReadQx 

Hematological support of patients with significant anemia who decline red blood cell blood transfusion.

Pubmed   Journal   ReadQx 

Homozygosity for the hyperunstable hemoglobin variant Hb Agrinio (HBA2:c.89T>C) leads to severe antenatal anemia: Eight new cases in three families.

Pubmed   Journal   ReadQx 

Momelotinib for myelofibrosis: 12-year survival data and retrospective comparison to ruxolitinib.

Pubmed   Journal   ReadQx 

Postremission cytopenia management in patients with AML treated with venetoclax and azacitidine in VIALE-A.

Pubmed   Journal   ReadQx 

Preliminary Efficacy and Safety of Relmacabtagene Autoleucel (Carteyva) in Adults with Relapsed/Refractory Follicular Lymphoma in China: A Phase I/II Clinical Trial.

Pubmed   Journal   ReadQx 

The Prevalence and Clinical Outcomes of Microangiopathic Hemolytic Anemia in Patients with Biopsy Proven Renal Thrombotic Microangiopathy.

The clinical spectrum of renal thrombotic microangiopathy (TMA) includes both the classic "Hemolytic uremic syndrome" (HUS) and a "Renal limited TMA" without systemic microangiopathic hemolytic anemia (MAHA).

Pubmed   Journal   ReadQx 

Use of CYP3Ai and impact on outcomes in patients with AML treated with venetoclax plus azacitidine in the VIALE-A study.

Pubmed   Journal   ReadQx 

Blood Cancer J

Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma.

Pubmed   Journal   ReadQx   PMC

High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.

Pubmed   Journal   ReadQx 

Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy.

Pubmed   Journal   ReadQx 

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.

Pubmed   Journal   ReadQx 

Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients.

Pubmed   Journal   ReadQx   PMC

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma.

Pubmed   Journal   ReadQx   PMC

Lancet Haematol

Factors to consider when assessing the IDOCS study - Authors' reply.

Pubmed   Journal   ReadQx 

Factors to consider when assessing the IDOCS study.

Pubmed   Journal   ReadQx 

Factors to consider when assessing the IDOCS study.

Pubmed   Journal   ReadQx 

Factors to consider when assessing the IDOCS study.

Pubmed   Journal   ReadQx 

Risk factors for neonatal thrombosis.

Pubmed   Journal   ReadQx